50,770 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by NFJ Investment Group LLC

NFJ Investment Group LLC purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 50,770 shares of the medical equipment provider's stock, valued at approximately $5,363,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Franklin Resources Inc. raised its position in shares of Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after buying an additional 2,796,372 shares during the period. Norges Bank purchased a new position in shares of Zimmer Biomet during the 4th quarter worth $216,223,000. Dodge & Cox raised its holdings in Zimmer Biomet by 12.0% in the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after buying an additional 2,044,645 shares during the period. Sound Shore Management Inc. CT purchased a new position in Zimmer Biomet during the fourth quarter worth about $81,447,000. Finally, FMR LLC lifted its holdings in shares of Zimmer Biomet by 91.6% in the 4th quarter. FMR LLC now owns 1,438,011 shares of the medical equipment provider's stock worth $151,897,000 after acquiring an additional 687,675 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

ZBH traded up $0.36 during trading on Tuesday, hitting $96.53. 256,611 shares of the stock were exchanged, compared to its average volume of 1,998,312. The firm has a market capitalization of $19.10 billion, a P/E ratio of 21.69, a PEG ratio of 1.95 and a beta of 0.84. The stock has a fifty day moving average price of $105.87 and a two-hundred day moving average price of $106.68. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 1-year low of $93.10 and a 1-year high of $123.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the company earned $2.20 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.99%. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.95% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. Stifel Nicolaus lifted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. Raymond James cut their price objective on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada cut their price target on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and an average target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.